|
Market Closed -
Euronext Paris
19:55:00 04/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.3810 EUR | -1.30% |
|
-1.04% | +27.85% |
| 09-02 | Nicox S.A. Announces Appointment of Doug Hubatsch as Chief Scientific Advisor | CI |
| 08-27 | The FDA will issue its decision on Nicox's NCX 470 by the end of next April |  |
| Market Cap | 33.58M 39.02M 31.59M 28.86M 53.99M 3.68B 54.13M 373M 145M 1.89B 147M 143M 6.09B | P/E 2026 * |
-7.62x | P/E 2027 * | 19.1x |
|---|---|---|---|---|---|
| Enterprise Value | 33.58M 39.02M 31.59M 28.86M 53.99M 3.68B 54.13M 373M 145M 1.89B 147M 143M 6.09B | EV / Sales 2026 * |
11.2x | EV / Sales 2027 * | 3.36x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
Euronext ParisEUR
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALCOX | Real-time | |
CBOE
| COXp | Real-time | |
|
Deutsche Boerse AG
| NXOA | Delayed | |
|
CBOE
| 0RCQ | Real-time | |
|
Börse Stuttgart
| NXOA | Delayed | |
|
Boerse Muenchen
| NXOA | Real-time |
| 1 day | -1.30% | ||
| 1 week | -1.04% | ||
| Current month | -2.06% | ||
| 1 month | -0.13% | ||
| 3 months | +1.87% | ||
| 6 months | -15.24% | ||
| Current year | +27.85% |
| 1 week | 0.38 |  | 0.39 |
| 1 month | 0.38 | | 0.4 |
| Current year | 0.29 | | 0.57 |
| 1 year | 0.28 | | 0.57 |
| 3 years | 0.14 | | 0.65 |
| 5 years | 0.14 | | 3.83 |
| 10 years | 0.14 | | 13.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
CEO | Chief Executive Officer | 55 | 28/02/2024 |
Sandrine Gestin
DFI | Director of Finance/CFO | 58 | 01/01/2015 |
Emmet Purtill
PRN | Corporate Officer/Principal | - | 01/01/2006 |
| Director | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
BRD | Director/Board Member | 55 | 08/04/2024 |
Damian Marron
CHM | Chairman | 64 | 16/07/2024 |
Marc Bozec
BRD | Director/Board Member | - | 16/07/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/01/22 | Free | Chief Executive Officer | 15,000 | 0.0348% | ||
| 16/02/21 | Exercice | Chief Executive Officer | 10,000 | 0.0270% | ||
| 01/02/20 | Free | Chief Executive Officer | 10,000 | 0.0300% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.30% | -1.04% | +6.13% | -12.61% | 39.02M | |
| -1.32% | +1.33% | +77.46% | +41.17% | 371B | |
| -1.45% | -3.14% | +24.01% | -18.97% | 68.64B | |
| -0.51% | +4.59% | +47.06% | +168.63% | 12.51B | |
| -1.09% | -9.76% | -8.26% | -8.91% | 8.06B | |
| +0.23% | -1.59% | -20.70% | +6.52% | 5.04B | |
| 0.00% | -4.12% | -31.60% | +22.10% | 4.51B | |
| -0.35% | -3.11% | -33.77% | +1.20% | 3.07B | |
| -1.00% | -0.46% | -5.37% | +37.45% | 2.53B | |
| -0.50% | -3.98% | -24.35% | -16.61% | 2B | |
| Average | -0.73% | -1.72% | +3.06% | +22.00% | 47.73B | |
| Weighted average by Cap. | -1.27% | +0.87% | +63.88% | +33.94% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3M 3.49M 2.82M 2.58M 4.82M 329M 4.84M 33.35M 12.94M 169M 13.09M 12.81M 544M | 10M 11.62M 9.41M 8.59M 16.08M 1.1B 16.12M 111M 43.14M 563M 43.64M 42.69M 1.81B |
| Net income | -5M -5.81M -4.7M -4.3M -8.04M -549M -8.06M -55.59M -21.57M -281M -21.82M -21.34M -907M | 2M 2.32M 1.88M 1.72M 3.22M 219M 3.22M 22.24M 8.63M 113M 8.73M 8.54M 363M |
| Net Debt | - | - |
Employees
10
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | €0.3810 | -1.30% | 106,909 |
| 03/09/26 | €0.3860 | +0.39% | 122,798 |
| 02/09/26 | €0.3845 | +0.39% | 108,178 |
| 01/09/26 | €0.3830 | -1.54% | 59,905 |
| 31/08/26 | €0.3890 | +1.04% | 90,111 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3810EUR
Average target price
1.000EUR
Spread / Average Target
+162.47%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALCOX Stock
Select your edition
All financial news and data tailored to specific country editions
